(CercleFinance.com) – OSE Immunotherapeutics announces that it has received innovation aid of 200,000 euros from the French Government and the Pays de la Loire Region, as part of the ‘France 2030’ investment plan operated by Bpifrance.
The company explains that this grant will ‘support it in the development of next-generation immunotherapies based on the unique strengths that therapeutic RNA could offer as a new first-in-class modality’.